Intellectual Property Rights and Access to Medicines

Abstract

The relationship between Intellectual Property Rights (IPRs) and access to medicines represents a critical intersection of innovation policy, international trade law, and public health governance. This study examines how patent protection and related intellectual property frameworks influence the affordability, availability, and distribution of essential medicines, particularly in low- and middle-income countries. It analyzes the role of international agreements such as the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the Doha Declaration on Public Health in balancing pharmaceutical innovation incentives with the right to health.
The research evaluates the economic justification for pharmaceutical patents, emphasizing their role in stimulating research and development (R&D) investments for new drugs and vaccines. At the same time, it critically explores concerns regarding high medicine prices, delayed generic competition, and inequitable access across regions. Special attention is given to policy tools such as compulsory licensing, parallel importation, patent pools, voluntary licensing, and public–private partnerships as mechanisms to reconcile intellectual property protection with public health objectives.
Through comparative analysis of policy responses during global health crises and in emerging economies, the study highlights the need for flexible intellectual property regimes that incorporate TRIPS flexibilities and promote technology transfer. The findings suggest that a balanced approach—supporting both pharmaceutical innovation and equitable access—is essential for sustainable global health outcomes. The study concludes that international cooperation and adaptive regulatory frameworks are vital to ensuring that intellectual property systems contribute positively to public health and social welfare.